FDA Finally Approves Bydureon

February 6th, 2012 written by Michael O’Leary

Try, try again. After three tries BYDUREON, the once-a-week version of Byetta received FDA approval last Friday, Jan. 27. The approval follows two earlier rejections by the FDA, which each time asked for more data.

BYETTA® (exenatide) was developed by Amylin Pharmeceuticals and Eli Lily. The twice-daily injection drug was the first glucagon-like peptide-1 (GLP-1) receptor agonist to be approved by the FDA for the treatment of type 2 diabetes. GLP-1 stimulates the release of insulin when glucose levels become too high. (Published site)

Is Victoza Better Than Bydureon?

September 22nd, 2011 by Ryan Luce No Comments

written by Michael O’Leary

Daily injections of liraglutide (Victoza) nosed out once-a-week injections of exenatide (Bydureon) in a head-to-head comparison in terms of reducing HbA1c, but type 2 diabetes patients using exenatide experienced fewer, milder side effects.

The results of the clinical trial were presented last week at the 47^th Annual meeting of the European Association for the Study of Diabetes last week in Lisbon, Portugal and was reported on by MedPage Today. (Link to published site)